ClinicalTrials.gg
CompletedNCT07432763Updated Feb 25, 2026

Effects of Pomegranate Seed Oil Supplementation in Patients With Advanced Dementia

An interventional study of Pomegranate Seed Oil Supplementation in Palliative Care Patients with Advanced Dementia and Care-as-usual in Urinary Tract Infections (UTIs), Urinary Tract Infection, Recurrent and Antipsychotics Discontinuation, sponsored by Panhellenic Federation of Alzheimer's Disease and Related Disorders. Completed at 1 site in Greece. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Panhellenic Federation of Alzheimer's Disease and Related Disorders · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled May 2024, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Urinary Tract Infections with a site in Greece — 1 open to participants now, 2 under way, none of them phase 3. Urinary Tract Infections · Greece.

Enrollment
11th of 12
18 · median 296
Started
2024
the only one that year
No phase
Only one
of the 20
Registered
20th of 20
by date

Among the 20 studies in Urinary Tract Infections with a site in Greece, this one is the 11th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2024, is the only one with no phase, and was the 20th registered.

Urinary Tract Infections

808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

1 of the 20 studies in Urinary Tract Infections with a site in Greece is open now. Recruiting first, the newest first:

A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Urinary Tract Infections with a site in Greece, or all of them as a file.
02

Study summary

The goal of this clinical study is to learn if Pomegranate Seed Oil supplementation works to combat urinary tract infections, recurrenturinary tract infections, or pneumonia and contributes to the tapering or discontinuation of antipsychotics in palliative care patients withadvanced dementia.

The main questions it aims to answer are:

  • Does Pomegranate Seed Oil supplementation reduce the likelihood of developing a urinary tract infection?
  • Does Pomegranate Seed Oil supplementation prevent UTI reinfection?
  • Does Pomegranate Seed Oil supplementation reduce the likelihood of pneumonia?
  • Does Pomegranate Seed Oil supplementation contribute to the tapering or discontinuation of antipsychotics?

Researchers will compare Pomegranate Seed Oil to care-as-usual to see if Pomegranate Seed Oil supplementation can increase quality of care in palliative care patients with advanced dementia.

03

Conditions studied

  • Urinary Tract Infections (UTIs)
  • Urinary Tract Infection, Recurrent
  • Antipsychotics Discontinuation
  • Antipsychotics Tapering

Keywords

  • Pomegranate Seed Oil
  • Mediterranean Diet
  • Palliative Care
  • Advanced Dementia
  • Patient Safety
  • Urinary Tract Infections
  • Antipsychotics
  • Randomized Clinical Trial
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 65+
  • Dementia diagnosis (major neurocognitive disorder) according to the criteria , Fifth Edition, Text Revision (DSM-5-TR) or the International Statistical Classification of Diseases and Related Health Problems (ICD-11)
  • Participants classified as Stage 7, Profound Cognitive Decline on the Global Deterioration Scale, corresponding to advanced dementia
  • AD related biomarkers in CSF
  • Caregiver consent for study participation

Exclusion criteria

Exclusion Criteria:

  • History of allergy to the supplement or any of its components
  • Prior diagnosis of Schizophrenia Spectrum and Other Psychotic Disorders according to the criteria , Fifth Edition, Text Revision (DSM-5-TR) or the International Statistical Classification of Diseases and Related Health Problems (ICD-11)
  • Participants having medical history of recurring urinary tract infections
  • Participants having medical history of renal or liver failure
  • Participants concurrently participating in other clinical studies
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Pomegranate Seed Oil

    Dietary Supplement: Pomegranate Seed Oil Supplementation in Palliative Care Patients with Advanced Dementia

  • Other
    Care-as-usual

    Other: Care-as-usual

Interventions

  • Dietary supplementPomegranate Seed Oil Supplementation in Palliative Care Patients with Advanced Dementia

    Besides Pomegranate Seed Oil Supplementation, all participants will continue to receive all ongoing care and treatments, including following the Mediterranean diet, monthly neuropsychological and behavioural assessments, physiotherapy, cognitive stimulation, occupational therapy and music therapy, without any modification

  • OtherCare-as-usual

    All participants will continue to receive all ongoing care and treatments, including a Mediterranean diet,monthly neuropsychological and behavioural assessments, physiotherapy, cognitive stimulation,occupational therapy and music therapy, without any modification

06

What researchers measure

Primary outcomes

  1. Number of Palliative Care Patients with Advanced Dementia with Urinary Tract Infections (UTIs)

    Urinary Tract Infections were diagnosed using the revised McGeer criteria for the diagnosis of UTIs in Stone et al. (2012): Criteria from both 1 and 2 1. At least 1 of the following: Acute dysuria or acute pain, swelling, or tenderness of the testes, epididymis, or prostate OR Fever or leukocytosis and at least 1 of the following localizing urinary tract sub-criteria: Acute costovertebral angle pain or tenderness Suprapubic pain Gross hematuria New or marked increase in incontinence New or marked increase in urgency New or marked increase in frequency In the absence of fever or leukocytosis, then 2 or more of the following: Suprapubic pain Gross hematuria New or marked increase in incontinence New or marked increase in urgency New or marked increase in frequency 2. One of the following: At least 10\^5 cfu/mL of no more than 2 species of microorganisms in a voided urine sample At least 10\^2 of any number of organisms in a specimen collected by in-and-out catheter

    Time frame: From enrollment to the end of treatment at 24 weeks

  2. Number of Palliative Care Patients with Advanced Dementia with Reccurent Urinary Tract Infections (rUTIs)

    Recurrent UTIs were classified as more than one UTI diagnosed in a single patient based on the criteria proposed in Stone et al. (2012) as described previously.

    Time frame: From enrollment to the end of treatment at 24 weeks

Secondary outcomes

  1. Number of Palliative Care Patients with Advanced Dementia with Antipsychotic Deprescribing (Dose Reduction or Discontinuation)

    Time frame: From enrollment to the end of treatment at 24 weeks

  2. Number of Palliative Care Patients with Advanced Dementia Diagnosed with Pneumonia

    As in Stone et al. (2012): All 3 criteria must be present: 1. Interpretation of a chest radiograph as demonstrating pneumonia or the presence of a new infiltrate 2. At least 1 of the following respiratory subcriteria 1. New or increased cough 2. New or increased sputum production 3. O2 saturation \<94% on room air or a reduction in O2 saturation of \>3% from baseline 4. New or changed lung examination abnormalities 5. Pleuritic chest pain 6. Respiratory rate of ≥25 breaths/min 3. At least 1 of the following criteria 1. Fever 2. Leukocytosis 3. Acute change in mental status from baseline and either disorganized thinking or altered level of consciousness 4. Acute functional decline

    Time frame: From enrollment to the end of treatment at 24 weeks

07

Study locations

1 site
  • Palliative Care Centre "Panagia Glykofilousa"
    Thessaloniki, Central Macedonia, Greece
08

References and documents

Publications

  • Stone ND, Ashraf MS, Calder J, Crnich CJ, Crossley K, Drinka PJ, Gould CV, Juthani-Mehta M, Lautenbach E, Loeb M, Maccannell T, Malani PN, Mody L, Mylotte JM, Nicolle LE, Roghmann MC, Schweon SJ, Simor AE, Smith PW, Stevenson KB, Bradley SF; Society for Healthcare Epidemiology Long-Term Care Special Interest Group. Surveillance definitions of infections in long-term care facilities: revisiting the McGeer criteria. Infect Control Hosp Epidemiol. 2012 Oct;33(10):965-77. doi: 10.1086/667743. PubMed 22961014 ↗

Individual participant data

Plan to share: No — Data Availability Statement The data supporting the findings of this study will not be publicly available due to GAADRD's internal policy to maintain the privacy of research participants and patients. However, the data will be available on reasonable request from the corresponding author.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Oct 2024, 5 months.

Of 136 non-industry interventional studies with no phase under Urinary Tract Infections, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 39. This study's 5 months is below that.

Counting every sponsor, half of 154 studies reached it within 22 months; a quarter within 8 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2026
First posted
Feb 25, 2026
StartActual
May 1, 2024
Primary completionActual
Oct 31, 2024
CompletionActual
Oct 31, 2024
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07432763
Lead sponsor
Panhellenic Federation of Alzheimer's Disease and Related Disorders
Collaborators
Greek Association of Alzheimer's Disease and Related Disorders (Alzheimer Hellas), RODI HELLAS SA
Responsible party
Sponsor
First posted
Feb 25, 2026
Start date
May 1, 2024
Primary completion
Oct 31, 2024
Completion
Oct 31, 2024
Last update
Feb 25, 2026

Study contacts

Magda Tsolaki
study chair · First Department of Neurology, Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
Ilias Maliousis
principal investigator · Greek Association of Alzheimer's Disease and Related Disorders (Alzheimer Hellas)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion